• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Adenovirus Infections - Pipeline Review, H2 2012 Product Image

Adenovirus Infections - Pipeline Review, H2 2012

  • Published: December 2012
  • 45 pages
  • Global Markets Direct

Adenovirus Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Adenovirus Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Adenovirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adenovirus Infections. Adenovirus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Adenovirus Infections.
- A review of the Adenovirus Infections products under development by companies READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Adenovirus Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Adenovirus Infections 7
Adenovirus Infections Therapeutics under Development by Companies 9
Adenovirus Infections Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Adenovirus Infections Therapeutics – Products under Development by Companies 14
Adenovirus Infections Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Adenovirus Infections Therapeutics Development 16
Chimerix, Inc. 16
Redox Pharmaceutical Corporation 17
Adenovirus Infections – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
CMX001 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
doxorubicin - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CMV specific cytotoxic T lymphocytes - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Cytotoxic T-Lymphocytes - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
hCAP-18/LL-37 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CD4 + CD8 T Cells - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Multi-Virus Cytotoxic T Lymphocytes - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Adenovirus Infections Therapeutics – Drug Profile Updates 34
Adenovirus Infections Therapeutics - Dormant Products 37
Adenovirus Infections – Product Development Milestones 38
Featured News & Press Releases 38
Apr 03, 2012: Chimerix To Present Data On CMX001 At Needham And Future Leaders Conferences 38
Jan 23, 2012: NovaBay Prepares To Launch Global Phase IIb Ophthalmic Study Of NVC-422 38
Jan 04, 2012: PsiOxus Announces Early Success Of Ark's Manufacturing Partnership With PsiOxus 39
Nov 09, 2011: Chimerix To Present Data On CMX001 At Upcoming Lazard And Piper Jaffray Healthcare Conferences 39
Jul 13, 2011: Chimerix Commences Phase II Study Of CMX001 For Prevention Of AdV In Ped & Adult Hematopoietic Stem Cell Transplant Patients 40
May 11, 2011: Chimerix's CMX001 Shows Antiviral Activity In Immunocompromised Transplant Patients With Severe Adenovirus Infection 41
Feb 24, 2011: Chimerix Announces Publication Of Successfully Treatment Of Adenovirus Infection Patient With CMX001 41
Jan 07, 2011: Chimerix Starts CMX001 Clinical Study For Treatment Of dsDNA Viral Infections 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products Under Development for Adenovirus Infections, H2 2012 7
Products under Development for Adenovirus Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Chimerix, Inc., H2 2012 16
Redox Pharmaceutical Corporation, H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Adenovirus Infections Therapeutics – Drug Profile Updates 34
Adenovirus Infections Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Adenovirus Infections, H2 2012 7
Products under Development for Adenovirus Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos